Abstract 1714
Background
Despite LNETs increasing in incidence and prevalence, little data exists about natural history and response to various therapies. Management is often based on expert opinion and extrapolation from other NETS. CommNETS and NANETS undertook a rigorous consensus process to endorse and update the 2015 ENETS guidelines (1).
Methods
An endorsement approach based on the AGREE II processes (2) was undertaken by a 4 nation, 22 member CommNETS/NANETS panel, including experts from: surgery, pulmonology, medical and radiation oncology, nuclear medicine, pathology, pharmacy and patients/advocates. Two members assessed content and quality of the 52 ENETS statements using the Rigour of Development subscale. A systematic literature and abstract search since 2013 was conducted. Topic experts reviewed relevant ENETS statements and new data, using a patient-centered care perspective and a LNET-specific focus, to provide justification for endorsement or modification and to define a single important unanswered question. Statements were subsequently discussed by the entire panel at a face-to-face meeting and graded using Oxford criteria (3).
Results
230 relevant new studies were identified. Of the 20 ENETS statements relating to management strategies, 4 were endorsed, 16 modified and 3 added (see table). A set of important unanswered questions will inform future studies.Table: 1322P
| Therapy | Main change |
|---|---|
| Surgery | updated techniques for localized disease modified followup protocol expanded indication for liver cytoreduction |
| Adjuvant | not recommended |
| Locoregional | optional for slow growing disease |
| Hormone | prophylaxis of carcinoid crisis added |
| PRRT | broadened to all SSTR-expressing tumours |
| Chemotherapy | newer data on temozolomide-based regimens included |
| Targeted | evidence for everolimus upgraded new statement, not supporting use of anti-angiogenics |
| Radiotherapy | palliative use for local symptoms added |
Conclusions
Through the consensus process, guidelines for LNETS were updated to include recent evidence and practice changes. The guidelines provide clear, evidenced based statements to harmonise treatment of LNETS internationally. Refs: 1.Caplin, Ann Oncology (2015):1604-1620. 2. http://www.agreetrust.org/resource-centre/agree-ii-as-a-practice-guideline-development-framework/ (30.4.18) 3. http://www.cebm.net/index.aspx?o=5653 (30.4.18).
Clinical trial identification
Legal entity responsible for the study
Australian Gastrointestinal Trials Group.
Funding
Ipsen Pty Ltd.
Editorial Acknowledgement
Disclosure
E. Segelov: Attendeded Advisory board: Ipsen Global. Ipsen funds CommNETS through an unrestricted grant to AGITG. This work was carried out by CommNETS. There was no involvement of Ipsen in any aspect of this research. All other authors have declared no conflicts of interest.
Resources from the same session
5720 - Evaluation of stemness and proliferation of human breast cancer stem cells (ALDH+) supplemented with heat-activated TGF-beta1 in the secretomes of stem cells from human exfoliated deciduous teeth (SHED)
Presenter: Septelia Wanandi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4844 - Estrogen-related receptor _ as a potential molecular target for endometrial cancer therapy
Presenter: TETSUYA KOKABU
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1200 - Good tolerability and limited target-specific tissue distribution of an anti-L1CAM antibody administered to cynomolgus monkey indicates favorable safety profile of L1CAM-targeting therapies
Presenter: Jacques Gaudreault
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2905 - Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma
Presenter: Anne Jouinot
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2597 - Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): final results from the prospective, observational CORRELATE study
Presenter: Juan Manuel O'Connor
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2663 - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Presenter: Julien Taieb
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1670 - Treatment pattern and outcomes of trifluridine/tipiracil therapy for metastatic colorectal cancer in the real-world data from the JFMC50 study
Presenter: Takeshi Kawakami
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD
Presenter: thomas Aparicio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2548 - Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer
Presenter: Toshiki Masuishi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis
Presenter: Katerina Kopeckova
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract